rTMS, Stress and Opioid Use Disorder

Opioid Use Disorder Clinical Trial

— TOTS  

Official title:

Using Neuromodulation to Investigate Treatment Pathways Associated With Stress and Substance Use in Opioid Use Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04920864
• Other study ID #: IRB-21-01-3111
• Status: Recruiting
• Phase: N/A
• Start date: April 1, 2022
• Est. completion date: December 2024

Study information

• Verified date: March 2024
• Source: Wayne State University
• Contact: Tabitha E Moses
• Phone: 313-577-8257
• Email: tmoses[@]med.wayne.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Opioid agonist treatments are the gold standard for treating opioid use disorder (OUD). Yet, even effective treatments average only 50% six-month retention. Despite extensive research into treatment options, it remains important to improve understanding of factors that contribute to relapse and identify interventions to mitigate these risks.

Stress-exposure is problematic for people trying to recover from substance use disorders (SUDs) because it weakens inhibition of automatic behaviors and increases drug craving and likelihood of relapse. However, paths through which stress affects behavior are incompletely understood and current SUD treatments do not target effects of stress on drug use.

This project will explore whether repetitive transcranial magnetic stimulation (rTMS) might improve treatment outcomes for people with OUD entering methadone treatment. The investigators will examine the impact of rTMS treatment over one of two theoretically-driven neural targets on substance use and cognitive outcomes associated with treatment success (executive function and emotional arousal).

Description:

The Competing Neurobehavioral Decisions Systems (CNDS) model of addiction suggests that people with SUDs have altered function and connectivity in fronto-cortical executive control regions (e.g. dorsolateral prefrontal cortex [dlPFC]) and fronto-cortical limbic control regions (e.g. medial prefrontal cortex [mPFC]). Namely, elevated activity in limbic circuitry results in hypersensitivity to drug cues and stress, and decreased executive control impairs the ability to resist drug urges. The CNDS theoretical framework can guide selection and testing of rTMS targets that could improve understanding of the mechanisms of SUDs and stress-induced drug use. Results from previous research suggest that therapeutic effects of rTMS for SUD could occur via excitation of dlPFC or inhibition of mPFC.

The investigators will administer excitatory (10Hz) dlPFC rTMS and inhibitory (1Hz) mPFC rTMS (through an electromagnetic coil placed against the scalp) coupled with tasks of executive function and emotional arousal during stress and neutral conditions (guided imagery task using personalized scripts) in adults with OUD early in methadone treatment. The investigators will examine and compare how strengthening dlPFC activity or reducing mPFC activity may reverse stress-induced executive and emotional dysfunction, respectively, and improve treatment outcomes in persons with OUD seeking to abstain from opioid use.

A mixed design study will be used to examine the effects of active rTMS vs. sham (within subject) over one of two locations: 10 Hz dlPFC rTMS (group 1) or 1 Hz mPFC rTMS (group 2) in subjects receiving methadone treatment for OUD. The general rTMS treatment protocol will be the same for both groups and will consist of 2 stimulation sessions per day, separated by ~30min, for 5 days (10 total stimulation sessions per treatment protocol). The sham protocol will be the same except the sham rTMS coil will be used. Participants will be randomly assigned to groups and complete the 2 conditions (active vs. sham rTMS) in random order. Immediately prior to and after each 5-day rTMS treatment protocol, participants will attend an assessment visit when they will complete multiple tasks during both stress (guided imagery stressor) and neutral conditions. These tasks are designed to measure executive function, emotional arousal, and drug-seeking behavior.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: December 2024
• Est. primary completion date: May 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Meet DSM-5 criteria for OUD;

2. In methadone or buprenorphine treatment

3. Age 21-70 yr;

4. Right handed;

5. Males and non-pregnant/non-lactating females;

6. Cognitively intact (total IQ score >80);

7. Use alcohol and/or marijuana <4 times per week; each "time" should consist of <2 marijuana "joint" equivalent and <4 alcoholic drinks.

Exclusion Criteria:

1. Acutely under the influence of any substance (except methadone or buprenorphine) during session;

2. Current, regular (>2 times/week) use of illicit drugs other than opioids (except cannabis);

3. Any past 24 hour use of drugs other than opioids or nicotine;

4. Urinalysis positive for pregnancy;

5. Medical conditions prohibiting use of rTMS;

6. Lifetime psychotic, bipolar, or potentially antisocial personality disorder;

7. Untreated or uncontrolled past-year diagnosis of major depression, generalized anxiety disorder, obsessive compulsive disorder, or post traumatic stress disorder;

8. Past-month SUD other than OUD or tobacco use disorder;

9. Acute/unstable illness making it unsafe for participation;

10. Any prohibited medications including: medications that lower seizure threshold, certain psychiatric medications, or prescription pain medications;

11. Chronic head or neck pain;

12. Past-month participation in a research study.

Related Conditions & MeSH terms

• Opioid Use Disorder
• Opioid-Related Disorders
• Substance-Related Disorders

Intervention

Device:
• rTMS
Repetitive transcranial magnetic stimulation

Locations

Country	Name	City	State
United States	Tolan Park Medical Building	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Wayne State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Wisconsin Card Sorting Task perseverance score	Wisconsin Card Sorting Task perseverance measures cognitive flexibility as an index of executive function. Higher scores reflect better outcome.	change from pre-intervention (day 0) to post-intervention (day 5) in the sham and active conditions
Primary	Emotional Arousal task rating	Average unpleasantness and arousal ratings in response to aversive pictures from the International Affective Picture System (IAPS). Lower unpleasantness and arousal scores reflect better outcome.	change from pre-intervention (day 0) to post-intervention (day 5) in the sham and active conditions
Primary	Opioid progressive ratio breakpoint	Opioid ($10 unit dose) vs. money ($2) hypothetical 10-trial choice task progressive ratio breakpoint is the highest response requirement completed for the drug on an exponentially increasing schedule of reinforcement, where the subject has to click the mouse an increasing number of times to earn drug or money. Lower breakpoint scores reflect better outcome.	change from pre-intervention (day 0) to post-intervention (day 5) in the sham and active conditions
Primary	Treatment success	Number of days of opioid use (based on timeline followback interview) during the 7 days following each 5-day rTMS (active and sham) period. Fewer days of opioid use reflect better outcome.	change from sham to active condition (randomized to occur on days 6-12 and 18-24, respectively)
Secondary	Digit Span total score	Digit Span (forward and backward) measures the extent of verbal working memory as an index of executive function. Higher scores reflect better outcome.	change from pre-intervention (day 0) to post-intervention (day 5) in the sham and active conditions
Secondary	Monetary delay discounting	Brief version of delay discounting task measures the immediate vs. delayed value of money. Higher area-under-the-curve scores (preference for delayed money) reflect better outcome.	change from pre-intervention (day 0) to post-intervention (day 5) in the sham and active conditions
Secondary	State-Trait Anxiety Inventory state anxiety total score	State anxiety subscale score of the State-Trait Anxiety Inventory. Lower scores reflect better outcome.	change from pre-intervention (day 0) to post-intervention (day 5) in the sham and active conditions
Secondary	Positive and Negative Affect Scale total score	Positive and Negative Affect Scale measures both positive and negative affect. Lower total negative affect scores reflect better outcome.	change from pre-intervention (day 0) to post-intervention (day 5) in the sham and active conditions